<DOC>
	<DOCNO>NCT00603889</DOCNO>
	<brief_summary>Na-ASP-2 protein express larval stage N. americanus hookworm life cycle . In clinical study previously hookworm-infected adult Brazil , protein induce urticarial reaction ( rash ) subset volunteer . This study evaluate solution vary concentration protein skin prick-puncture intradermal test eventually use screen volunteer live hookworm endemic area consider potential participant vaccine trial , reduce potential inducing allergic reaction vaccinate Na-ASP-2 Hookworm Vaccine .</brief_summary>
	<brief_title>Development Skin Test Na-ASP-2 Hookworm Antigen</brief_title>
	<detailed_description>- Study site : George Washington University Medical Center - Number participant : 15 - Study duration : 3 month ; participant undergo minimum one screen visit one study visit . - Each participant skin prick-puncture intradermal skin test apply study day . The prick-puncture intradermal test apply sequentially volar aspect participant 's forearm : 1 . Skin prick-puncture : four different concentration Na-ASP-2 solution ( 1 , 10 , 100 , 1000 μg/mL ) apply simultaneously duplicate , leave forearm . 2 . Intradermal : three different concentration Na-ASP-2 ( 10 , 100 , 1000 μg/mL ) inject simultaneously , duplicate , right forearm . 3 . Allergen diluent histamine solution utilized negative positive control , respectively , skin prick-puncture intradermal test . 4 . Participants observe study clinic least 30 minute follow application skin test , contact via telephone 2 day follow skin test . 5 . Sizes wheal erythema reaction application record graded comparison histamine positive control reaction . - Each participant blood collect via venipuncture ( maximum 25 mL ) immediately prior application skin test , order measure antibody ( particularly IgG IgE ) Na-ASP-2 use ELISA procedure .</detailed_description>
	<mesh_term>Hookworm Infections</mesh_term>
	<mesh_term>Ancylostomiasis</mesh_term>
	<criteria>Males females 18 45 year age , inclusive . Good general health determine mean screening procedure . Willingness participate study evidence sign informed consent document . History previous infection hookworm . Prior extensive continuous travel , work , residence ( &gt; 1 month ) hookwormendemic region . Pregnancy determine positive urine hCG test ( female ) . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history physical examination . Behavioral , cognitive , psychiatric disease opinion investigator affect ability volunteer understand cooperate study protocol . Other condition opinion investigator would jeopardize safety right volunteer participate trial would render subject unable comply protocol . Participation investigational vaccine drug trial within 14 day start study . Volunteer medical , occupational , family problem result alcohol illicit drug use past 12 month . History severe allergic reaction anaphylaxis . Known immunodeficiency syndrome . Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day start study . History surgical splenectomy . Extensive dermatitis preclude skin test Current use beta blocker ( oral topical ) antihistamine medication . A volunteer may participate study agree withhold use antihistamine least 5 day prior application skin test . Use tricyclic antidepressant within past month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Hookworm</keyword>
	<keyword>Allergy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Skin test</keyword>
</DOC>